There are currently 417 clinical trials in Grand Rapids, Michigan looking for participants to engage in research studies. Trials are conducted at various facilities, including Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Spectrum Health - Butterworth Campus, Trinity Health Grand Rapids Hospital and CCOP - Grand Rapids. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
The MIRROR Registry: Minimally Invasive IntRaceRebral HemORrhage Evacuation
NCT04494295
Recruiting
This registry will study the use of the Aurora® Surgiscope to provide surgical access and visualization in minimally invasive removal of hematoma in the brain. Many methods of hematoma removal are available and will be based on surgeon preference. The impact of patient selection and time to surgery from last known well time will be explored.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Corewell Health, Grand Rapids, Michigan
Conditions: Supratentorial Hemorrhage
Register for Updates
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738
Recruiting
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Research Site, Grand Rapids, Michigan
Conditions: Non-small Cell Lung Cancer
Register for Updates
Medtronic Terminate AF Study
NCT03546374
Recruiting
The purpose of this study is to demonstrate the safety and effectiveness of the Cardioblate iRF and CryoFlex hand held devices for the treatment of non-paroxysmal atrial fibrillation (AF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Corewell Health, Grand Rapids, Michigan
Conditions: Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation
Register for Updates
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
NCT06063850
Recruiting
The main goals of this clinical study are to learn if AMT-260 is safe and tolerable and works to reduce the frequency of seizures in adults with unilateral mesial temporal lobe epilepsy (MTLE).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/24/2025
Locations: Corewell Health, Grand Rapids, Michigan
Conditions: Mesial Temporal Lobe Epilepsy
Register for Updates
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
NCT05065216
Recruiting
This is a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and medium vessel occlusions. This study focuses on participants with limited treatment options. Participants who have or will receive mechanical thrombectomy (MT) are not eligible for participation. Additionally, participants who have received fibrinolytics are excluded unl... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/24/2025
Locations: Trinity Health Grand Rapids Hospital, Grand Rapids, Michigan
Conditions: Acute Stroke, Ischemic Stroke, Stroke
Register for Updates
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
NCT05612035
Recruiting
Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take frespaciguat can walk farther in 6 minutes at Week 24 compared to people who take placebo.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
07/24/2025
Locations: Corewell Health ( Site 0133), Grand Rapids, Michigan
Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Register for Updates
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
NCT05067634
Recruiting
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
07/23/2025
Locations: Spectrum Health Hospitals Helen DeVos Children's Hospital, Grand Rapids, Michigan
Conditions: Partial Epilepsy
Register for Updates
A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
NCT05067283
Recruiting
This is a study evaluating the safety, pharmacokinetics, and efficacy of MK-1084 alone, and MK-1084 plus other combination therapies in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: START Midwest ( Site 0267), Grand Rapids, Michigan
Conditions: Advanced Solid Tumors
Register for Updates
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
NCT00736749
Recruiting
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
Gender:
ALL
Ages:
All
Trial Updated:
07/22/2025
Locations: Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan
Conditions: Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
Register for Updates
Distal Ischemic Stroke Treatment With Adjustable Low-profile Stentriever
NCT05152524
Recruiting
The objective of the DISTALS Study is to evaluate the safety and effectiveness of the Tigertriever 13 Revascularization Device in restoring blood flow in the neurovasculature by removing thrombus in patients presenting within 24 hours of onset with an ischemic stroke with disabling neurological deficits due to a primary distal vessel occlusion (DVO), as compared to medical management.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/22/2025
Locations: Corewell Health (Spectrum), Grand Rapids, Michigan
Conditions: Ischemic Stroke, Neovascularization
Register for Updates
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT05887492
Recruiting
The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question\[s\] it aims to answer are: * the recommended dose for Phase 2 * to evaluate the safety and tolerability of the combination therapy * to determine the pharmacokinetics of TNG260 * to evaluate the initial antineoplastic activity Participants will receive study treatment until they exp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: START MidWest, Grand Rapids, Michigan
Conditions: Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma
Register for Updates
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NCT07029399
Recruiting
The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1 amplification). Main questions to answer include: * What is the recommended dose for expansion and/or Phase 2 * What medical issues/symptoms do participants experience when taking NKT5097
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan
Conditions: HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer, Ovarian Cancer, Endometrial Cancer, Uterine Carcinosarcoma
Register for Updates